Amgen (AMGN) vs Gilead Sciences (GILD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Amgen (AMGN) has outperformed Gilead Sciences (GILD) over the past year, gaining 39.8% versus a gain of 25.7%. Over five years, GILD leads with a +117.1% price change compared with +98.7% for AMGN. Amgen is the larger company by market cap ($223.32 billion vs $182.09 billion), about 1.2 times the size.
On valuation, Gilead Sciences trades at a lower forward P/E (14.8x vs 16.9x for Amgen). Amgen offers the higher dividend yield (2.37% vs 2.19%). Gilead Sciences converts more of its revenue into profit, with a net margin of 28.9% versus 21.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AMGN | GILD |
|---|---|---|
| Share price | $413.08 | $146.85 |
| Market cap | $223.32B | $182.09B |
| 1-day change | +2.60% | +1.82% |
| YTD return | +26.20% | +19.64% |
| 1-year return | +39.77% | +25.75% |
| 5-year return | +98.75% | +117.14% |
| P/E ratio (TTM) | 25.66 | — |
| Forward P/E | 16.88 | 14.85 |
| EPS (TTM) | $16.10 | $-2.65 |
| Dividend yield | 2.37% | 2.19% |
| Annual dividend | $9.80 | $3.22 |
| Revenue (latest FY) | $36.75B | $29.44B |
| Revenue growth (YoY) | +9.95% | +2.40% |
| Net income (latest FY) | $7.71B | $8.51B |
| Gross margin | 67.25% | 78.83% |
| Operating margin | 24.71% | 34.04% |
| Net margin | 20.98% | 28.90% |
| 52-week high | $447.03 | $157.29 |
| 52-week low | $288.00 | $114.02 |
| Distance from 52-week high | -7.59% | -6.64% |
| Analyst consensus | hold | buy |
| Avg. price target upside | -5.23% | +8.46% |
| Average volume | 2.72M | 6.02M |
| Shares outstanding | 540.63M | 1.24B |
| Employees | 31,500 | 17,000 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AMGN has outperformed GILD by 14.0 percentage points over the past year.
- Gilead Sciences is more profitable, keeping 28.9 cents of every revenue dollar as net income versus 21.0 cents for Amgen.
- Amgen grew revenue faster in its latest fiscal year (+9.95% vs +2.40%).
About Amgen
AMGN stock →Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 31,500 employees
About Gilead Sciences
GILD stock →Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 17,000 employees
AMGN vs GILD FAQ
Which is bigger, Amgen or Gilead Sciences?
Amgen (AMGN) is larger, with a market capitalization of $223.32B compared with $182.09B for Gilead Sciences (GILD).
Which stock has performed better over the past year, AMGN or GILD?
AMGN returned +39.77% over the past 12 months, compared with +25.75% for GILD (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Amgen or Gilead Sciences?
Amgen has the higher yield at 2.37%, compared with 2.19% for Gilead Sciences.
Are Amgen and Gilead Sciences in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.